Kim A. Papp, M.D read ., Ph.D., Craig Leonardi, M.D., Alan Menter, M.D., Jean-Paul Ortonne, M.D., James G. Krueger, M.D., Gregory Kricorian, M.D., Girish Aras, Ph.D., Juan Li, Ph.D., Chris B. Russell, Ph.D., Elizabeth H.Z. Thompson, Ph.D., and Scott Baumgartner, M.D.S. Population2,3 and 0.6 to 6.5 percent of the European population.4 Emerging data identify a subset of helper T cells, Th17, that preferentially make interleukin-17 and play a significant function in orchestrating inflammation in psoriasis.5-7 Levels of interleukin-17 are elevated in the lesional epidermis and blood of patients with psoriasis5,8-10 and correlate with disease severity.11 The interleukin-17 cytokine family includes six cytokines and five receptors .12 The interleukin 17A, 17F, and 17A/F heterodimer ligands talk about a common receptor subunit for signaling.16 The forming of imiquimod-induced skin damage resembling psoriasis is blocked in mice that are deficient in interleukin-17RA.17 These data claim that cytokine-targeting strategies aimed at blocking signaling through interleukin-17RA could be beneficial in the treating psoriasis.
Related StoriesSausages With Antioxidants From Berries To Prevent CancerCornell biomedical engineers develop 'super organic killer cells' to eliminate malignancy cells in lymph nodesNew findings reveal association between colorectal malignancy and melanoma drug treatmentThe project, which will be carried out at the Centenary Institute, brings together researchers with expertise in basic research and the clinic, with the aim of exploring inflammation and tumor at the cellular and molecular level. The synergistic and combinatorial use of basic and clinical skills gives a high likelihood of discoveries resulting in new therapies. ‘This research is very important because inflammation and cancer are in the heart of several human diseases. This particularly applies to the major global issue of liver fibrosis and liver malignancy affecting almost half a billion of the world’s people,’ Professor Vadas said.